Dose-dense sequential adriamycin-paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer

Oncology

Volumn 68, Issue 4-6, 2005, Pages 446-453

  Kahan, Zsuzsanna ^a,b   Uhercsak, Gabriella ^a   Hajnal Papp, Rozalia ^a   Boda, Krisztina ^a   Thurzo, Laszlo ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NONE   (Hungary)

Author keywords

Breast cancer; Chemotherapy; Cyclophosphamide; Doxorubicin; Filgrastim; GCSF; Paclitaxel; Toxicity

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; PACLITAXEL; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER GRADING; CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART ARRHYTHMIA; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IATROGENIC DISEASE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; PACLITAXEL;

EID: 23844472936     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086987     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930-942.
2. Nowak AK, Wilcken NRC, Stockler MR, Hamilton A, Ghersi D: Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004;5:372-380.
3. Hudis C: The use of taxanes in early breast cancer. Eur J Cancer 2003;(suppl 1):1-10.
4. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
5. Norton L: Adjuvant breast cancer therapy: Current status and future strategies - Growth kinetics and the improved drug therapy of breast cancer. Semin Oncol 1999;26:1-4.
6. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Lancet 2000;356:1384-1391.
7. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JPA, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L: Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy. J Clin Oncol 1999;17:97-100.
8. Hudis CA: Dose-dense paclitaxel-containing adjuvant therapy for breast cancer. Oncology (Huntingt) 1998;(suppl 1):16-18.
9. Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L: 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. J Clin Oncol 1999;17:1118-1126.
10. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P: Increased intensification and total dose of cyclophosphamide in a doxorubicin- cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858-1869.
11. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Febrenbacher L, Henry PH, Ramond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999;17:3374-3388.
12. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
13. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL Jr, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM: High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002;20:743-750.
14. Buzzoni R, Bonnadonna G, Valagussa P, Zambetti M: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2134-2140.
15. Bonnadonna G, Zambette M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 1995;273:542-547.
16. Fountzilas G, Papadimitriou C, Aravantinos G, Nicolaides C, Stathopoulos G, Bafaloukos D, Kalofonos H, Ekonomopoulos T, Skarlos D, Pavlidis N, Dimopoulos AM: Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. Oncology 2001;60:214-220.
17. Silber JH, Fridman M, Shpilsky A, Even-Shoshan O, Smink DS, Jayaraman J, Fox KR, Pauly MV: Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998;16:2435-2444.
18. Rivera E, Haim Erder M, Fridman M, Frye D, Hortobagyi GN: First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: A validation study. Breast Cancer Res 2003;5:114-120.
19. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N: Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28 (abstract). Proc ASCO 2003;22:12.